Abstracts tagged "evidence-based practice"

Abstract Number: 051 • 2020 Pediatric Rheumatology Symposium
Pediatric Providers’ Perspectives on Suspected Immune-Mediated Diffuse Alveolar Hemorrhage and Clinical Care Pathways
Jessica Bloom¹ and Robert Fuhlbrigge ², ¹Children's Hospital Colorado, Aurora, Colorado, ²University of Colorado, Aurora
Background/Purpose: Immune-mediated diffuse alveolar hemorrhage (iDAH) is a life-threatening complication of pediatric rheumatologic diseases such as vasculitis, systemic lupus erythematosus, and antiphospholipid antibody syndrome. Delay…
Abstract Number: 2844 • 2018 ACR/ARHP Annual Meeting
A Mixed-Methods Feasibility Study Exploring the Cultural Adaptation of Walk with Ease to the United Kingdom
Kathryn R Martin^1,2, Toby O Smith³, Santosh Gaihre⁴, Gary J Macfarlane^1,2, Aileen Neilson⁵, Paul McNamee⁵, Rosalind Rae⁶ and Zoe J Morrison⁷, ¹Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, ²Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴School of Biomedical Sciences, Ulster University, Coleraine, United Kingdom, ⁵Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom, ⁶Business School, University of Aberdeen, Aberdeen, United Kingdom, ⁷Human Resources and Organisational Behaviour, University of Greenwich, London, United Kingdom
Background/Purpose: The Arthritis Foundation’s Walk With Ease (WWE) is an evidence-based 6 week community-based walking program for adults with arthritis delivered in instructor-led or self-directed…
Abstract Number: 1398 • 2016 ACR/ARHP Annual Meeting
Practice-Based Differences Between Pediatric Rheumatologists and Dermatologists Caring for Children with Discoid Lupus
Lisa Arkin¹, Kaveh Ardalan², Heather Brandling-Bennett³, Yvonne Chiu⁴, Benjamin Chong⁵, Megan Curran⁶, Raegan Hunt⁷, Amy Paller⁸, Victoria P. Werth^9,10, Marisa Klein-Gitelman⁶, Emily von Scheven¹¹ and for the CARRA SLE workgroup, ¹Department of Dermatology and Pediatrics;, University of Wisconsin School of Medicine & Public Health/American Family Children’s Hospital, Madison, WI, ²Division of Rheumatology; Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Dermatology; Department of Pediatrics, Seattle Children’s Hospital/University of Washington School of Medicine, Seattle, WA, ⁴Department of Dermatology and Pediatrics, Medical College of Wisconsin / Children's Hospital of Wisconsin, Milwaukee, WI, ⁵Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁶Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Departments of Dermatology and Pediatrics, Baylor College of Medicine / Texas Children’s Hospital, Houston, TX, ⁸Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine/Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁹Dermatology, University of Pennsylvania, Philadelphia, PA, ¹⁰Dermatology, Veterans Affairs Medical Center, Philadelphia, PA, ¹¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA
Background/Purpose: Discoid lupus erythematosus (DLE) is rare in children. There are no consensus guidelines for management or screening for evolution to systemic lupus erythematosus (SLE).…
Abstract Number: 2385 • 2015 ACR/ARHP Annual Meeting
Arthritis Management in Primary Care and Adherence to National Guidelines – a Swedish Survey Based on the Canadian Physiotherapists Arthritis Care Questionnaire
Siv Folkhammar Andersson¹, Stefan Bergman^2,3,4 and Ann Bremander^3,4,5, ¹Unit of Rehabilitation, Kalmar County Council, Samrehab, Oskarshamn, Sweden, Oskarshamn, Sweden, ²Primary Health Care Unit, Department of Public Health and Community Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴FoU Spenshult, Halmstad, Sweden, ⁵School of Business, Engineering and Science, Halmstad University, Halmstad, Sweden
Background/Purpose: For patients with osteoarthritis (OA) physical therapy is recommended first line treatment and performed in primary care while patients with rheumatoid arthritis (RA) may…
Abstract Number: 2279 • 2014 ACR/ARHP Annual Meeting
Evidence Based Recommendations for Diagnosis and Management of Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS)
Nienke ter Haar¹, Paul Brogan², Gilles Grateau³, Jordi Anton⁴, Karyl Barron⁵, Luca Cantarini⁶, Joost Frenkel⁷, Caroline Galeotti⁸, Veronique Hentgen⁹, Michael Hofer¹⁰, Tilmann Kallinich¹¹, Isabelle Kone-Paut¹², Jasmin Kuemmerle-Deschner¹³, Huri Ozdogan¹⁴, Seza Ozen¹⁵, Ricardo Russo¹⁶, Anna Simon¹⁷, Yosef Uziel¹⁸, Carine Wouters¹⁹, Brian Feldman²⁰, Bas Vastert⁷, Nico Wulffraat²¹, Helen Lachmann²² and Marco Gattorno²³, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology Unit, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ³Service De Médecine Interne, Hopital Tenon, Paris, France, ⁴Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, ⁵NIH, Bethesda, MD, ⁶University of Siena, Siena, Italy, ⁷University Medical Center Utrecht, Utrecht, Netherlands, ⁸Bicêtre Hospital, University of Paris SUD, Paris, France, ⁹Versailles Hospital, Le Chesnay Cedex, France, ¹⁰Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ¹¹Charite, University Medicine Berlin, Berlin, Germany, ¹²Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, ¹³Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ¹⁴Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ¹⁵Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ¹⁶Immunology & Rheumatology, Hospital De Pediatria, Buenos Aires, Argentina, ¹⁷Radboudumc, Nijmegen, Netherlands, ¹⁸Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ¹⁹University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, ²⁰Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²¹Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²²UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ²³Istituto Giannina Gaslini, Genova, Italy
Background/Purpose Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS) is a rare hereditary autoinflammatory syndrome that can lead to significant morbidity. Evidence-based guidelines are lacking…
Abstract Number: 2282 • 2014 ACR/ARHP Annual Meeting
Evidence Based Recommendatinos for Diagnosis and Management of Mevalonate Kinase Deficiency (MKD)
Nienke ter Haar¹, Jerold Jeyaratnam², Jordi Anton³, Caroline Galeotti⁴, Karyl Barron⁵, Paul Brogan⁶, Luca Cantarini⁷, Marco Gattorno⁸, Gilles Grateau⁹, Veronique Hentgen¹⁰, Michael Hofer¹¹, Tilmann Kallinich¹², Isabelle Kone-Paut¹³, Jasmin Kuemmerle-Deschner¹⁴, Helen Lachmann¹⁵, Huri Ozdogan¹⁶, Seza Ozen¹⁷, Ricardo Russo¹⁸, Yosef Uziel¹⁹, Carine Wouters²⁰, Brian Feldman²¹, Bas Vastert², Nico Wulffraat²², Anna Simon²³ and Joost Frenkel², ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands, ³Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, ⁴Bicêtre Hospital, University of Paris SUD, Paris, France, ⁵NIH, Bethesda, MD, ⁶Rheumatology Unit, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁷University of Siena, Siena, Italy, ⁸Istituto Giannina Gaslini, Genova, Italy, ⁹Service De Médecine Interne, Hopital Tenon, Paris, France, ¹⁰Versailles Hospital, Le Chesnay Cedex, France, ¹¹Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ¹²Charite, University Medicine Berlin, Berlin, Germany, ¹³Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, ¹⁴Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ¹⁵UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁶Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ¹⁷Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ¹⁸Immunology & Rheumatology, Hospital De Pediatria, Buenos Aires, Argentina, ¹⁹Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ²⁰University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, ²¹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²²Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²³Radboudumc, Nijmegen, Netherlands
Background/Purpose Mevalonate kinase deficiency (MKD) is a rare hereditary autoinflammatory syndrome that can lead to significant morbidity. Evidence-based guidelines are lacking and management is mostly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].